Report Overview

China Adrenoleukodystrophy (ALD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP). Globally AMN and cALD are the two most common phenotypes of X-ALD, which account for 45% and 35% respectively. The global incidence of X-ALD is approximately 6.2/100,000 live births. X-ALD is included in the first China Rare Disease Catalogue published in 2018.The age of onset of cALD patients is typically 4-8 years old.



Market Drivers

China is a growing market for adrenoleukodystrophy (ALD) due to increase in global incidence rate (6.2/100,000 live births). In addition to this, other factors that contribute to the growth of the market are inevitable inheritance of the disease and increase in R&D activities by pharmaceutical companies.

However, there are some restraining factors for growth of adrenoleukodystrophy (ALD) drugs market in China such as overall high cost of treatment and unfavourable reimbursement.